The effectiveness of tailored E-health self-management treatment for patients with end-stage renal disease: A randomized controlled trial

The effectiveness of tailored E-health self-management treatment for patients with end-stage renal disease: A randomized controlled trial - E-HELD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON50543

Enrollment

130

Registered

2018-06-14

Start date

2019-02-27

Completion date

Unknown

Last updated

2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage renal disease (ESRD) Kidney Disease

Interventions

The E-health self-management treatment is based on evidence-based cognitive-behavioral principles and aims to reduce the impact of the disease on daily life, by optimizing how a patient copes with t

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • End-stage renal disease (GFR = 18 years of age • Sufficient command of the Dutch language

Exclusion criteria

Exclusion criteria: • Serious medical conditions that are likely to interfere with completion of the study (such as progressive malignancy or other debilitating illness) at the discretion of the nephrologist • A life expectancy

Design outcomes

Primary

Measure	Time frame
As primary outcome measure, the effects of the treatment on distress will be examined.	—

Secondary

Measure	Time frame
As secondary outcome measures, the effectiveness of the treatment on 4 domains will be examined: 1. change in disease-specific self-efficacy and self-management 2. changes in relevant aspects of functioning related to the treatment modules (e.g., coping with fatigue, pain, itch, negative mood and social functioning) 3. meaningful improvements on the areas of interest to the patients (using a personalized outcome measure) 4. cost-effectiveness of the treatment (the profits of the intervention in terms of health care use and societal participation as compared to the extra costs of the treatment in addition to care as usual	—

Measure

Time frame

As secondary outcome measures, the effectiveness of the treatment on 4 domains will be examined: 1. change in disease-specific self-efficacy and self-management 2. changes in relevant aspects of functioning related to the treatment modules (e.g., coping with fatigue, pain, itch, negative mood and social functioning) 3. meaningful improvements on the areas of interest to the patients (using a personalized outcome measure) 4. cost-effectiveness of the treatment (the profits of the intervention in terms of health care use and societal participation as compared to the extra costs of the treatment in addition to care as usual

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)